Other ongoing TCR therapy trials include: E7 TCR treatment in HLA-A*02:01-positive patients with relapsed/refractory HPV16-positive cancers (KITE-439, NCT03912831); HPV-E6-specific TCR T-cell transfer in HPV-positive HNSCC (NCT03578406); autologous TIL infusion (LN-145/LN-145-S1) followed by IL-2 administration in patients with R/M HNSCC (NCT03083873). This evidence concerns the gene IL2 and cancer.